News Focus
News Focus
Followers 843
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

Re: None

Tuesday, 11/06/2007 4:44:32 PM

Tuesday, November 06, 2007 4:44:32 PM

Post# of 3757
IDX-899 in vitro data shows that it does not generate cross-resistance to Sustiva. Hence, IDX-899 could theoretically be given earlier in HIV treatment than Sustiva (or Atripla) is given. (Source: Today’s CC)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”